Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The global oncology market is charging toward a massive $668 billion valuation by 2034[1], fueled by a...
Roth MKM analyst Jonathan Aschoff maintained a Buy rating on GeoVax Labs today and set a price target of $14.00. The company’s shares closed yesterday at $0.56.Elevate Your Investing Strategy: Take advantage...
/CNW/ -- As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing uncertainty. The situation is...
Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As World Cancer Day (Feb. 4) fades into the rearview, attention is shifting to the latest discussions...
Issued on behalf of BioVaxys Technology Corp. VANCOUVER – USA News Group – According to the World Health...
GeoVax Labs receives patent allowance, enhancing its intellectual property for cancer immunotherapy using its unique viral vector platform.Quiver AI SummaryGeoVax Labs, Inc. announced that the U.S. Patent...
Vuzix, GeoVox Labs, and Cardiol Therapeutics emerged as notable penny stocks late in 2024 for their potential to scale operations and launch new products.
GeoVax Labs announces CEO David Dodd will present at NobleCon20 on corporate updates and clinical trials.Quiver AI SummaryGeoVax Labs, Inc., a biotechnology company focused on human vaccines and cancer...
Emergent Biosolutions and Chimerix also saw marginal gains after the announcement.